Got 90 seconds? Then listen to AdAlta’s managing director and CEO tell us about how the company’s flagship drug product is progressing in the market.

Established in 2007, AdAlta (ASX:1AD) is a drug company that is developing a treatment for idiopathic pulmonary fibrosis (IPF), known as scarring of the lungs, and other fibrotic diseases.

The company’s lead drug, AD-214, is based on antibodies or proteins that the immune system uses to kill off invaders or bacteria. In particular, the drug has antibodies that mimic those that keep sharks healthy. The result is a range of unique compounds for use in treating serious diseases.

Stockhead caught up with AdAlta’s managing director and CEO Sam Cobb at this week’s Coffee Microcaps Conference in Sydney and we asked her to give us an update on AD-214 and what investors should expect from the company in the near future.

Have a good idea for our next 90 Seconds With segment? Email us at [email protected]